Elle est la tumeur primitive du cerveau la plus fréquente et la plus agressive et qui devrait emporter plus de 12000 personnes cette année aux USA et plus d'une dizaines de milliers d'autres à travers le monde.
Pour 1.000 patients diagnostiqués, moins de 500 survivent un an après le diagnostic ! L'espérance de vie à cinq ans de cette maladie a peu évolué ces trente dernières années, et ne dépasse pas les dix pour cent. Même avec une résection chirurgicale complète de la tumeur, combinée aux meilleurs traitements disponibles, le taux de survie au GBM reste très faible.
Une coalition internationale sans précédent a vu le jour pour lancer des nouveaux essais cliniques. Cette coalition mondiale regroupe plus de 150 participants dont plus de 40 institutions spécialisées sur la recherche contre le cancer réparties sur les quatre continents.
Il y a 2 ans, Olivia Newton-John a perdu sa soeur Rona de cette maladie agressive et via la création du Olivia Newton-John Cancer Research Institute, elle peut désormais supporter cette coalition !
Olivia Newton-John GBM from ASU Now on Vimeo.
Two and a half years ago, Olivia Newton-John lost her beloved sister Rona to glioblastoma multiforme (GBM), the world’s most common and highly aggressive brain tumour. Sadly she watched her sister die, unable to help. In a continuation of her ongoing commitment to find a cure for cancer Olivia has given her support and that of the Olivia Newton-John Cancer Wellness & Research Centre towards the launch of GBM AGILE – a ground breaking global alliance that aims to find effective treatments for this deadly disease.
GBM AGILE is a global coalition of GBM neuro-surgeons, neuro-oncologists, basic and clinical investigators as well as representatives from the GBM advocacy community who share the conviction that the dismal survival statistics of GBM – a five year survival rate of less than two percent – are unacceptable.
Although literally hundreds of clinical trials around the world have tested numerous therapies for GBM, treatment options and patient outcomes have not changed for several decades.
This global coalition have come together to design and plan for a new generation of clinical trials for GBM where the learnings from each patient within a trial will inform the ongoing conduct of the trial. This innovative approach aims to test many drugs and combinations of therapies vs single agents – and do it faster.
Olivia said, ‘No one should have to watch someone they love suffer and die without hope. GBM AGILE will help us learn together which treatments work. This sharing of learning worldwide is critical if we want to change the outcome of this terrible disease.”
“This is a very exciting new approach that will accelerate treatment discovery for patients with GBM,” said Associate Professor Hui Gan from the Olivia Newton-John Cancer Research Institute.
It is anticipated that there will be GBM trial sites based in Sydney, Melbourne and Brisbane with the locations announced in February 2016.
The Olivia Newton-John Cancer Wellness & Research Centre is one of the leading brain cancer trial sites in Australia. Currently at the Centre there a number of promising GBM clinical trials in progress.
Olivia said, “On behalf of myself and my team at the Olivia Newton-John Cancer Wellness & Research Centre in Melbourne we are delighted to support the GBM AGILE trial and we are proud to be part of a coalition that cares.”
Read more at Olivia Newton-John Cancer research Institute.
Twitter : https://twitter.com/hashtag/GBMAGILE?src=hash
Aucun commentaire:
Enregistrer un commentaire